CM-3: Phase I started

Biocompatibles' CellMed AG unit began a double-blind, placebo-controlled, German Phase I trial to evaluate single ascending doses of CM-3 in 56 healthy male volunteers. AstraZeneca plc (LSE:AZN; NYSE...